Time to capitalise on Hikma’s ongoing (share price) momentum
17/05/24 -"We have incorporated higher royalty payments in 2024 related to the sale of the generic version of sodium oxybate (medicine to treat symptoms of narcolepsy, i.e. sudden muscle weakness and excessive ..."
Pages
56
Language
English
Published on
17/05/24
You may also be interested by these reports :
17/09/25
The massive collapse in Novo Nordisk’s share price over the last 15 months, due to competitive concerns, pricing pressure and a few other factors, ...
25/08/25
Attractive return potential remains – Confidence slightly raised
22/08/25
Though missing expectations, Novonesis demonstrated strong momentum in H1 2025, achieving 9% organic growth and 8% in Q2, resulting in a narrowed ...
21/08/25
Guidance reaffirmed while FX and destocking mask momentum